

[Anatomic Pathology Abstracts, 5/16](#)

written by CAP TODAY
May 18, 2016

May 2016—Noninfectious aortitis of the ascending aorta: a histological and clinical correlation of cases; Stratifying HPV-induced cervical pathology using E4 with p16 or MCM; Limited resection versus lobectomy for older patients with early-stage lung cancer; L1CAM expression and its association with mutant p53 expression in endometrial cancer; Value of p16 staining for predicting outcome of LSIL/CIN1



©2026 CAP TODAY, all rights reserved.

[Q&A column, 5/16](#)

written by CAP TODAY
May 18, 2016

May 2016—What laboratory test should be used to monitor the effect of the heart failure medication Entresto (sacubitril/valsartan)? After getting a consultation report, I usually issue an addendum without changing my own diagnosis. Some of my colleagues use an amended report with their own diagnosis changed. They say this will help clinicians with patient management. I do not feel confident about many of these difficult cases, so I do not want to change my diagnosis. We would like to establish a department policy to address this. Can you provide guidance?



©2026 CAP TODAY, all rights reserved.

Newsbytes, 5/16

written by CAP TODAY
May 18, 2016

May 2016—Sunquest acquires GeneInsight; Technidata launches lab system; HHS seeks feedback on measuring growth of interoperability in health IT; Xifin upgrades collaboration and clinical data-management platform; Kalorama Information releases report on global LIS market; Aspyra announces LIS installation



©2026 CAP TODAY, all rights reserved.

Put It on the Board, 5/16

written by CAP TODAY
May 18, 2016

May 2016—FDA approves Abbott companion diagnostic for CLL; SelectMDx study published in European Urology; Quest Zika test authorized for emergency use; Epigenomics receives FDA approval for Epi proColon; Leica to collaborate on companion diagnostic



©2026 CAP TODAY, all rights reserved.

IVD antibodies for IHC, 5/16

written by CAP TODAY
May 18, 2016

May 2016—Bio SB is offering 50 new antibodies for in vitro diagnostic applications. This generation of antibodies offers higher affinity, sensitivity, and specificity when compared with the previous generation of mouse monoclonal and polyclonal antibodies traditionally used in diagnostic immunohistochemistry applications. “Our new RBT and EP clones of rabbit monoclonal antibodies are unique reagents for cancer research and diagnostics,” Alfonso Heras, DVM, PhD, president and CEO of Bio SB, said in a statement. Among them are BRAF V600E, B7/H3, CD163, CTLA-4, *Helicobacter pylori*, MDM2, NKX3.1, OX-40, SATB2, SMAD4, STAT6, and others.

Bio SB, 805-692-2768



©2026 CAP TODAY, all rights reserved.

PCR system, assay receive medical device license, 5/16

written by CAP TODAY
May 18, 2016

May 2016—Luminex received medical device licenses from Health Canada’s Therapeutic Products Directorate, Medical Devices Bureau, for the Aries System and Aries HSV 1&2 Assay; both were FDA cleared in October 2015 and were subsequently launched in the U.S. market.



©2026 CAP TODAY, all rights reserved.

3-D in vivo confocal microscope, 5/16

written by CAP TODAY

May 18, 2016

May 2016—MR Solutions' 3-D in vivo confocal microscope for use in preclinical research provides a magnification range of up to 1,000 times, allowing researchers to examine cellular details within a live small animal, eliminating the need for a surgical biopsy.



©2026 CAP TODAY, all rights reserved.

Microinjection-ready Cas9 accelerate RNP, 5/16

written by CAP TODAY

May 18, 2016

May 2016—Horizon Discovery Group introduced its microinjection-ready Cas9 Accelerate Ribonucleoprotein. Cas9 Accelerate RNP maximizes gene-editing efficiency by enabling CRISPR ...



©2026 CAP TODAY, all rights reserved.

Sysmex signs distribution agreement with

Medline, 5/16

written by CAP TODAY
May 18, 2016

May 2016—Sysmex America has signed a nonexclusive distributor agreement with Medline Industries, a manufacturer and distributor of health care supplies.



©2026 CAP TODAY, all rights reserved.

Genomic test to predict prostate cancer progression, 5/16

written by CAP TODAY
May 18, 2016

May 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.



©2026 CAP TODAY, all rights reserved.